The pooled analysis revealed a significantly increased risk of CRC among patients receiving GLP-1 RAs (RR, 2.31; 95% CI, 1.82–2.93; I2 = 36%; p < 0.0001). This evidence concerns the gene GCG and colorectal carcinoma.